The Journal Pulse - Hematologic Oncology kapak görseli

The Journal Pulse - Hematologic Oncology

The Journal Pulse - Hematologic Oncology

Yazan: The Journal Pulse Team
Şimdi ücretsiz dinle, üyelik gerekmez

This Season's Biggest Deal | £0.99/mo for 3 months + £10 Audible bonus

£5.99/mo after 3 months - terms apply. Cancel monthly
Özet
 Weekly discussions on the latest evidence in hematologic oncology - from landmark trials to practice-changing papers.The Journal Pulse Team Hygiene & Healthy Living Physical Illness & Disease
Bölümler
  • Bortezomib in T-Cell ALL: Did Adding a Proteasome Inhibitor Move the Needle for Kids with the Hardest Leukemia to Treat?

    Bortezomib in T-Cell ALL: Did Adding a Proteasome Inhibitor Move the Needle for Kids with the Hardest Leukemia to Treat?
    15 Jul 2026

    One landmark clinical paper, dissected every week.

    pulsosaudepodcast@gmail.com


    ARTICLE REFERENCE:

    • Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma
    • Authors: Teachey DT, Devidas M, Wood BL et al.
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • https://doi.org/10.1200/JCO.21.02678
    Daha fazlasını göster Daha Az Göster
    25 dk.
  • High-Dose Cytarabine and Vorinostat in AML: When Intensification Meets Epigenetics

    High-Dose Cytarabine and Vorinostat in AML: When Intensification Meets Epigenetics
    8 Jul 2026

    One landmark clinical paper, dissected every week.

    pulsosaudepodcast@gmail.com


    ARTICLE REFERENCE:

    • A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
    • Authors: Garcia-Manero G, Podoltsev NA, Othus M et al.
    • Journal: Leukemia
    • https://doi.org/10.1038/s41375-023-02073-x
    Daha fazlasını göster Daha Az Göster
    24 dk.
  • CANOVA Trial: Venetoclax-Dexamethasone vs Pomalidomide-Dexamethasone in t(11;14) Relapsed/Refractory Multiple Myeloma

    CANOVA Trial: Venetoclax-Dexamethasone vs Pomalidomide-Dexamethasone in t(11;14) Relapsed/Refractory Multiple Myeloma
    1 Jul 2026

    One landmark clinical paper, dissected every week.

    pulsosaudepodcast@gmail.com


    ARTICLE REFERENCE:

    • Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study
    • Authors: Popat R, Beksac M, Dimopoulos MA et al.
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • https://doi.org/10.1200/JCO-25-00924
    Daha fazlasını göster Daha Az Göster
    27 dk.
adbl_web_anon_alc_button_suppression_t1
Henüz yorum yok